

THOSE MOST LIKELY TO NEED AN ALZHEIMER'S TREATMENT ARE UNDERREPRESENTED IN CLINICAL TRIALS

African Americans, Native Americans, Hispanics, and Asian Americans/Pacific Islanders are all disproportionately affected by Alzheimer's; however, they are underrepresented in Alzheimer's clinical trials where crucial research is done to find treatments or a cure for this deadly disease.



INEQUITY IN RESEARCH STUNTS PROGRESS

The underrepresentation of these populations limits the ability of researchers to understand health disparities, and it restricts knowledge of how an approved therapy or diagnostic may affect those most likely to need the treatment.



A FOUNDATION FOR SUCCESS ALREADY EXISTS

The National Institute on Aging (NIA) has established centers across the country that offer support and opportunities to participate in Alzheimer's research, and they are well-positioned to increase education and outreach activities to underrepresented populations within their communities, including:

- 33 Alzheimer's Disease Research Centers (ADRCs) at major medical institutions.
- 4 Exploratory ADRCs designed to expand and diversify research and education opportunities to new areas of the country and new populations.
- 8 Alzheimer's disease-focused Resource Centers for Minority Aging Research (RCMARs) to enhance the diversity of the clinical trial staff by mentoring promising scientists from underrepresented groups.



THE ENACT ACT WOULD HAVE A MEANINGFUL IMPACT ON YOUR COMMUNITY AND CONSTITUENTS

- The ENACT Act would provide funding for NIA to expand the number of ADRCs in areas with higher concentrations of underrepresented populations, through entities like Historically Black Colleges and Universities (HBCUs), Hispanic-Serving Institutions, Tribal Colleges and Universities (TCUs), or centers of excellence for other underrepresented populations.
- The ENACT Act would provide funding for ADRCs and RCMARs to increase education and outreach

to underrepresented communities and primary care physicians to let them know about current trial opportunities, the importance of participation, and the disparate impact of the disease on their populations.

- ADRCs and RCMARs would use community-based engagement strategies in their outreach to underrepresented populations, including community presentations, media outreach, community advisory boards, and flagship events.

SUPPORT THE BIPARTISAN EQUITY IN NEUROSCIENCE AND ALZHEIMER'S CLINICAL TRIALS (ENACT) ACT

(S. 1548/H.R. 3085)

to increase the participation of underrepresented populations in Alzheimer's and other dementia clinical trials

#ENACTAct
alzimpact.org